We may earn a commission for purchases through links on our site at no cost to you, Learn more. All trademarks and brand names are the property of their respective owners. All Wegovy product and service names used in this website are for informational purposes only. Use of these names and brands does not imply endorsement.
Wegovy is a prescription medication used for chronic weight management in adults and adolescents. Approved by the FDA in 2021, Wegovy contains the active ingredient semaglutide, which belongs to a class of drugs called glucagon-like peptide-1 (GLP-1) receptor agonists. This medication is administered as a once-weekly subcutaneous injection and is intended to be used alongside a reduced-calorie diet and increased physical activity.
What is Wegovy?
The primary use of Wegovy is to help individuals with obesity or overweight with at least one weight-related comorbidity lose weight and keep it off. For adults, it’s indicated for those with a body mass index (BMI) of 30 kg/m² or greater (obesity), or 27 kg/m² or greater (overweight) with at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol. In adolescents aged 12 and older, it’s prescribed for those with a BMI in the 95th percentile or higher for their age and sex.
Wegovy works by mimicking the action of the naturally occurring hormone GLP-1, which plays a crucial role in regulating appetite and food intake. By activating GLP-1 receptors in the brain, Wegovy helps to reduce hunger, increase feelings of fullness, and lower calorie intake. This mechanism of action leads to significant weight loss in many patients when combined with lifestyle changes.
In March 2024, the FDA expanded Wegovy’s approval to include reducing the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease who are either obese or overweight. This additional indication was based on clinical trial results demonstrating Wegovy’s ability to lower the risk of major adverse cardiovascular events in this population.
Like all medications, Wegovy can cause side effects. The most common side effects include nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, and dizziness. These side effects are usually mild to moderate and tend to decrease over time as the body adjusts to the medication. However, Wegovy also carries a boxed warning about the potential risk of thyroid C-cell tumors, based on studies in rodents. It should not be used in patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2.
Wegovy’s effectiveness for weight loss has been demonstrated in several clinical trials. In the STEP (Semaglutide Treatment Effect in People with Obesity) clinical trial program, participants taking Wegovy lost an average of 15-18% of their initial body weight over 68 weeks, compared to 2-3% in the placebo group. These results were significantly better than those seen with other currently available weight loss medications.
It’s important to note that Wegovy is intended for long-term use in weight management. It’s not a quick fix or short-term solution, but rather a tool to be used as part of a comprehensive weight management program that includes dietary changes and increased physical activity. Patients should work closely with their healthcare providers to determine if Wegovy is appropriate for them and to monitor their progress and any potential side effects throughout treatment.
How much is Wegovy?
The cost of Wegovy has been a topic of considerable discussion among healthcare providers, patients, and insurance companies.
The list price of Wegovy, as set by its manufacturer Novo Nordisk, is $1,349.02 for a 28-day supply. This translates to approximately $337.25 per week or an annual cost of around $17,585 for those paying out-of-pocket. It’s important to note that this price reflects the cost without any insurance coverage or discounts applied. For many individuals, this high price tag can be a significant barrier to accessing the medication.
However, the actual cost that patients pay for Wegovy can vary widely depending on several factors, including insurance coverage, pharmacy pricing, and available savings programs. For those with commercial insurance that covers Wegovy, the out-of-pocket cost can be significantly lower. Some patients may pay as little as $0 for a 28-day supply, subject to a maximum savings of $225 per fill for up to 13 fills, through the Wegovy Savings Card program offered by Novo Nordisk.
For individuals without insurance coverage or those whose insurance doesn’t cover Wegovy, there are still options to reduce costs. The Wegovy Savings Card program offers savings of up to $500 for a 28-day supply for eligible cash-paying patients or those with commercial insurance that doesn’t cover the medication. Additionally, various prescription discount programs and cards, such as those offered by SingleCare or Optum Perks, may provide some savings on the list price.
It’s worth noting that the cost of Wegovy extends beyond just the medication itself. Patients need to factor in the expenses associated with healthcare provider visits, which are necessary for obtaining and managing the prescription. These costs can vary depending on whether patients opt for in-person visits or telehealth services, with the latter often being more affordable.
For those covered by Medicare or Medicaid, the situation is more complex. Currently, Medicare does not cover medications specifically for obesity management, although some Medicare Advantage plans may offer coverage. Medicaid coverage varies by state, so patients need to check with their state’s Medicaid office for specific information.
Given the high cost of Wegovy, many patients and healthcare providers are exploring alternative medications that may be more affordable. Other GLP-1 receptor agonists, such as Ozempic (which contains the same active ingredient as Wegovy but at a lower dose), may be prescribed off-label for weight loss and could be less expensive, with a list price of around $935.77 per pen.
In summary, while the list price of Wegovy is substantial at $1,349.02 for a 28-day supply, the actual cost to patients can vary significantly. Through a combination of insurance coverage, manufacturer savings programs, and discount cards, many patients may be able to access Wegovy at a more affordable price. However, the high cost remains a significant consideration for both patients and healthcare systems, highlighting the ongoing challenges in making effective weight loss treatments accessible to those who need them.
How effective is Wegovy compared to other GLP-1 receptor agonists like Ozempic and Saxenda?
Based on the available data, Wegovy (semaglutide 2.4 mg) appears to be more effective for weight loss compared to other GLP-1 receptor agonists like Ozempic (semaglutide at lower doses) and Saxenda (liraglutide). Here’s a comparison of their effectiveness:Wegovy (semaglutide 2.4 mg):
- In clinical trials, patients lost an average of 15-18% of their initial body weight over 68 weeks .
- About 83% of patients achieved ≥5% weight loss, and 66% achieved ≥10% weight loss .
- A recent study showed that patients maintained an average weight loss of 10.2% for up to 4 years .
Ozempic (semaglutide 0.5 mg, 1 mg, or 2 mg):
- While not indicated for weight loss, Ozempic showed average weight loss of 9.3 to 14.1 lbs (4.2 to 6.4 kg) in diabetes trials .
- In the SUSTAIN 5 trial, patients lost an average of 8.6 lbs (3.9 kg) with the 1 mg dose over 30 weeks .
Saxenda (liraglutide 3.0 mg):
- In a 56-week study, patients lost an average of 5-10% of their initial body weight .
- About 63% of patients achieved ≥5% weight loss, and 33% achieved >10% weight loss .
- Mean weight loss was 8.0% (18.7 lbs or 8.5 kg) with Saxenda compared to 2.6% (6.1 lbs or 2.8 kg) with placebo .
Key differences:
- Magnitude of weight loss: Wegovy consistently shows higher average weight loss (15-18%) compared to Saxenda (5-10%) and Ozempic (4-6%).
- Proportion of patients achieving significant weight loss: A higher percentage of patients on Wegovy achieve ≥5% and ≥10% weight loss compared to Saxenda.
- Long-term effectiveness: Recent data shows Wegovy maintains significant weight loss (10.2%) for up to 4 years, which is longer than previously documented for other GLP-1 receptor agonists .
- Dosing: Wegovy is administered once weekly, while Saxenda requires daily injections. Ozempic is also once weekly but at lower doses than Wegovy.
- Primary indication: Wegovy and Saxenda are specifically approved for weight management, while Ozempic is primarily indicated for type 2 diabetes treatment with weight loss as a secondary benefit.
It’s important to note that individual responses to these medications can vary, and the choice of treatment should be made in consultation with a healthcare provider, considering factors such as the patient’s medical history, potential side effects, and treatment goals.
How does Wegovy help you lose weight?
Wegovy (semaglutide) is a revolutionary prescription medication that has shown remarkable effectiveness in helping people lose weight. This injectable drug works by mimicking a hormone called glucagon-like peptide-1 (GLP-1), which plays a crucial role in regulating appetite and food intake. By targeting areas of the brain responsible for appetite control, Wegovy helps individuals feel fuller for longer periods and reduces overall calorie consumption.
The mechanism of action of Wegovy is multifaceted. As a GLP-1 receptor agonist, it activates receptors in the brain that are involved in appetite regulation. This activation leads to decreased hunger sensations and increased feelings of fullness. Additionally, Wegovy slows down gastric emptying, which means food stays in the stomach longer, contributing to prolonged satiety. These combined effects result in a natural reduction in calorie intake without the need for strict dieting or willpower alone.
Clinical trials have demonstrated the impressive weight loss potential of Wegovy. In a 68-week study, participants using Wegovy lost an average of 15-18% of their initial body weight. This is significantly more than what is typically seen with other weight loss medications or lifestyle interventions alone. Furthermore, about 83% of people taking Wegovy achieved a weight loss of 5% or more, and 66% lost 10% or more of their body weight. These results highlight the drug’s ability to produce substantial and clinically meaningful weight reduction.
One of the key benefits of Wegovy is its long-term effectiveness. Recent studies have shown that patients can maintain significant weight loss for up to four years with continued use of the medication. This is particularly important because many weight loss interventions struggle with long-term sustainability. The ability to maintain weight loss over an extended period can have profound positive impacts on overall health and reduce the risk of weight-related comorbidities.
It’s important to note that Wegovy is not a magic solution for weight loss. It is designed to be used as part of a comprehensive weight management program that includes a reduced-calorie diet and increased physical activity. The medication enhances the effectiveness of these lifestyle changes by making it easier for individuals to adhere to their diet and exercise plans. By reducing hunger and cravings, Wegovy helps patients stick to their calorie goals more easily and consistently.
The dosing of Wegovy is carefully structured to minimize side effects while maximizing weight loss benefits. Treatment typically starts with a lower dose that is gradually increased over time. This approach allows the body to adjust to the medication and reduces the likelihood of gastrointestinal side effects, which are the most common adverse reactions associated with Wegovy.
While Wegovy has shown impressive results, it’s not suitable for everyone. It is specifically indicated for adults with a body mass index (BMI) of 30 kg/m² or greater (obesity) or 27 kg/m² or greater (overweight) with at least one weight-related comorbidity. It’s also approved for use in adolescents aged 12 and older with a BMI in the 95th percentile or higher for their age and sex. As with any medication, potential users should consult with their healthcare provider to determine if Wegovy is appropriate for their individual circumstances.
In summaery, Wegovy helps people lose weight by targeting the brain’s appetite control centers, reducing hunger, increasing feelings of fullness, and slowing gastric emptying. Its effectiveness has been demonstrated in clinical trials, showing significant and sustained weight loss over time.
When used as part of a comprehensive weight management program, Wegovy can be a powerful tool in the fight against obesity and its related health complications.
How much weight do you lose in a month with Wegovy?
Wegovy (semaglutide) has emerged as a highly effective medication for weight loss, but it’s important to understand that weight loss results can vary significantly from person to person. While clinical trials provide valuable data on average weight loss, individual experiences may differ based on factors such as starting weight, diet, exercise habits, and adherence to the medication regimen.
In the first month of Wegovy treatment, many users report noticeable weight loss, though the exact amount can vary widely. According to clinical trial data and real-world experiences, patients might expect to lose anywhere from 5 to 15 pounds (2.3 to 6.8 kg) in the first month. However, it’s crucial to note that this initial weight loss can be more rapid due to factors like water weight and initial metabolic changes, and the rate of weight loss typically slows down in subsequent months.
One study found that people who received weekly semaglutide injections lost an average of about 15 pounds after three months, which translates to approximately 5 pounds per month. This aligns with the general guideline that a safe and sustainable rate of weight loss is about 1-2 pounds per week or 4-8 pounds per month. However, some individuals may experience more dramatic results, especially in the early stages of treatment.
Real-world experiences shared by Wegovy users offer insights into the potential for rapid initial weight loss. For instance, one patient reported losing about 16 kg (approximately 35 pounds) in the first month of treatment. While this is an exceptional case and not typical, it illustrates the potential for significant early weight loss in some individuals. It’s important to emphasize that such rapid weight loss is not common or necessarily sustainable for most people.
The dosing schedule of Wegovy also plays a role in the weight loss timeline. The medication is typically started at a low dose and gradually increased over several weeks to minimize side effects. This means that the full weight loss potential of Wegovy may not be realized until patients reach the maintenance dose, which usually occurs around week 17 of treatment. Therefore, the weight loss experienced in the first month may not be representative of the long-term results.
Long-term data from clinical trials provide a more comprehensive picture of Wegovy’s effectiveness. After one year of treatment, adults taking Wegovy lost an average of 15% of their body weight, which equates to about 35 pounds for a person starting at 232 pounds (the average starting weight in the trials). This translates to an average monthly weight loss of about 3 pounds after the initial rapid loss phase.
It’s crucial to understand that Wegovy is not a quick fix but rather a tool to be used in conjunction with lifestyle changes. The medication works by helping to reduce appetite and increase feelings of fullness, but it’s most effective when combined with a reduced-calorie diet and increased physical activity. Patients who adhere to these lifestyle modifications along with their Wegovy treatment are more likely to see consistent and sustainable weight loss over time.
Healthcare providers typically set realistic expectations for their patients, emphasizing that while some may see rapid initial results, others may experience more gradual weight loss. The goal is sustainable, long-term weight management rather than rapid, short-term loss. Patients are often advised to focus on overall health improvements, such as better blood pressure or blood sugar control, rather than solely on the number on the scale.
How much weight can you lose in 3 months with Wegovy?
Many individuals are curious about the potential results Wegovy can achieve in a relatively short timeframe, such as three months. Based on clinical trials and real-world data, Wegovy has shown significant efficacy in promoting weight loss within this period.
In the first three months of Wegovy treatment, most individuals can expect to lose approximately 5% to 10% of their initial body weight. This translates to about 10 to 20 pounds for someone starting at 200 pounds. However, it’s important to note that individual results can vary considerably based on factors such as starting weight, adherence to the medication regimen, diet, and physical activity levels.
Clinical trials have demonstrated impressive results for Wegovy. In the STEP 1 trial, which was a 68-week study, participants lost an average of 6% of their body weight by week 12 (approximately three months). This early weight loss is particularly encouraging, as it can provide motivation for individuals to continue with their weight loss journey.
Real-world data has largely corroborated these clinical findings. A study published in JAMA Network Open examined the effectiveness of weekly semaglutide therapy in a real-world setting. At the three-month mark, patients experienced a mean weight loss of 6.7 kg (about 14.8 pounds), which equated to a 5.9% reduction in body weight. This aligns closely with the results observed in controlled clinical trials.
It’s worth noting that Wegovy is typically initiated at a lower dose and gradually increased over time to minimize side effects. This means that the full weight loss potential of the medication may not be realized until after the first three months when patients reach the target dose of 2.4 mg per week. Therefore, some individuals might experience even greater weight loss in the months following the initial three-month period.
The weight loss achieved with Wegovy in the first three months can have significant health benefits. Even a modest weight loss of 5% to 10% can improve various obesity-related conditions, such as high blood pressure, high cholesterol, and type 2 diabetes. Many patients report feeling more energetic and experiencing improved mobility within this timeframe.
However, it’s crucial to understand that Wegovy is not a magic solution and works best when combined with lifestyle modifications. Patients who couple their Wegovy treatment with a reduced-calorie diet and increased physical activity will likely see more substantial results. Healthcare providers typically recommend a comprehensive approach that includes nutritional counseling and support for behavior changes alongside the medication.
It’s also important to consider that not everyone will respond to Wegovy in the same way. Some individuals may experience more rapid weight loss, while others might see slower progress. Factors such as age, sex, baseline BMI, and the presence of other medical conditions can all influence the rate and extent of weight loss.
In summary, while individual results may vary, most people using Wegovy can expect to lose between 5% and 10% of their body weight in the first three months of treatment. This translates to a significant amount of weight loss for many individuals and can serve as a strong foundation for continued progress in their weight management journey. As with any medical treatment, it’s essential to work closely with a healthcare provider to monitor progress, manage any side effects, and adjust the treatment plan as needed to achieve optimal results.
Who should not take Wegovy?
Wegovy (semaglutide) is a highly effective medication for weight loss, but it is not suitable for everyone. There are several groups of people who should not take Wegovy due to potential risks or contraindications.
Individuals with a personal or family history of medullary thyroid carcinoma (MTC) should not use Wegovy. This rare type of thyroid cancer has been associated with the use of GLP-1 receptor agonists like semaglutide in animal studies. While the risk in humans is not fully understood, the FDA has issued a boxed warning about this potential risk. Similarly, people with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), a rare genetic condition that increases the risk of certain endocrine tumors, including MTC, are advised against using Wegovy.
Pregnant women or those planning to become pregnant should not take Wegovy. The medication may harm the developing fetus, and it is recommended that women stop using Wegovy at least two months before planning to conceive. Controlling weight during pregnancy is important, but the potential risks of Wegovy to the unborn child outweigh its benefits in this context. Breastfeeding mothers should also avoid Wegovy, as it is unknown whether the drug passes into breast milk and what effects it might have on nursing infants.
People with a history of pancreatitis should not use Wegovy, as the medication has been associated with an increased risk of this condition. Additionally, individuals with severe gastrointestinal diseases, including gastroparesis or inflammatory bowel disease, may not be suitable candidates for Wegovy due to its effects on digestive processes.
Those with a history of suicidal thoughts or behaviors, or severe depression, should use Wegovy with caution and under close medical supervision. While not strictly contraindicated, the medication has been associated with an increased risk of suicidal ideation in some patients, and mental health should be closely monitored during treatment.
Patients with advanced kidney disease may need to avoid Wegovy or use it with caution, as the medication is primarily eliminated through the kidneys. The safety and efficacy of Wegovy in patients with severe renal impairment have not been established, and dose adjustments may be necessary for those with moderate kidney dysfunction.
Individuals who are allergic to semaglutide or any of the inactive ingredients in Wegovy should not use the medication. Allergic reactions can be severe and potentially life-threatening, so it’s crucial to disclose any known allergies to healthcare providers before starting treatment.
Lastly, Wegovy should not be used in combination with other semaglutide-containing products or other GLP-1 receptor agonists. This includes medications like Ozempic, Rybelsus, or Trulicity, as combining these drugs could lead to an overdose of the active ingredient.
It’s important to note that while these contraindications are significant, they don’t apply to everyone. Many people can safely and effectively use Wegovy for weight management under proper medical supervision. Always consult with a healthcare provider to determine if Wegovy is appropriate based on individual health status, medical history, and current medications.
What is the difference between Wegovy and Ozempic?
Wegovy and Ozempic are both injectable medications containing the active ingredient semaglutide, but they have some key differences in their approved uses, dosages, and effectiveness for weight loss.
The primary distinction between Wegovy and Ozempic lies in their FDA-approved indications. Wegovy is specifically approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity.
It’s also approved for weight management in adolescents aged 12 and older with a BMI in the 95th percentile or higher for their age and sex. Ozempic, on the other hand, is primarily approved for improving blood sugar control in adults with type 2 diabetes and reducing the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.
While both medications contain semaglutide, they differ in their dosages. Wegovy is available in higher doses, with a maximum dose of 2.4 mg once weekly. Ozempic, designed for diabetes management, has a maximum dose of 2 mg once weekly.
This difference in dosage contributes to their varying effectiveness for weight loss. In clinical trials, Wegovy demonstrated more significant weight loss results, with patients losing an average of 15-18% of their initial body weight over 68 weeks. Ozempic, while not officially approved for weight loss, has shown weight loss as a side effect, with patients losing an average of 9.3 to 14.1 lbs (4.2 to 6.4 kg) in diabetes trials.
The side effect profiles of Wegovy and Ozempic are similar due to their shared active ingredient, but the higher dosage of Wegovy may lead to more pronounced effects. Common side effects for both include gastrointestinal issues such as nausea, vomiting, diarrhea, and constipation. However, the frequency and severity of these side effects tend to be higher with Wegovy. For example, nausea occurs in about 44% of Wegovy users compared to 15-20% of Ozempic users.
Another important distinction is in their intended use duration and effects on weight maintenance. Wegovy is designed for long-term use in weight management, with recent studies showing that patients maintained an average weight loss of 10.2% for up to 4 years with continued use. Ozempic, while used long-term for diabetes management, has not been studied as extensively for long-term weight loss maintenance.
Insurance coverage and cost can also differ between the two medications. Ozempic, being primarily a diabetes medication, is more likely to be covered by health insurance plans. Wegovy, as a weight loss medication, may have more limited coverage and can be more expensive for patients.
It’s worth noting that while Ozempic is sometimes prescribed off-label for weight loss, this use is not FDA-approved. Healthcare providers may consider this off-label use in certain situations, but it’s generally recommended to use Wegovy for weight loss purposes due to its higher dosage and specific approval for this indication.
In conclusion, while Wegovy and Ozempic share the same active ingredient, they are distinct medications with different approved uses, dosages, and effectiveness for weight loss.
Wegovy is specifically designed and approved for weight management, offering higher doses and potentially greater weight loss results. Ozempic, primarily a diabetes medication, can lead to weight loss as a secondary effect but at lower levels compared to Wegovy. The choice between these medications should be made in consultation with a healthcare provider, considering the individual’s specific health needs, treatment goals, and potential side effects.
What are the differences in side effects between Wegovy and Ozempic?
While Wegovy and Ozempic both contain semaglutide as their active ingredient, there are some differences in their side effect profiles due to their different dosages and approved uses. Here’s a comparison of their side effects:Similarities in side effects:
- Gastrointestinal issues: Both medications commonly cause nausea, vomiting, diarrhea, constipation, and abdominal pain. These are the most frequently reported side effects for both drugs.
- Headache: This is a common side effect for both Wegovy and Ozempic.
- Fatigue: Users of both medications may experience tiredness.
- Risk of thyroid tumors: Both carry a boxed warning for the potential risk of thyroid C-cell tumors, based on animal studies.
- Potential for pancreatitis, gallbladder problems, and kidney issues.
Key differences:
- Frequency and severity of side effects: Wegovy, being used at higher doses for weight management, tends to have a higher incidence of side effects, particularly gastrointestinal ones. For example:
- Nausea occurs in about 44% of Wegovy users compared to 15-20% of Ozempic users.
- Diarrhea affects about 30% of Wegovy users versus 8.5% of Ozempic users.
- Weight loss-related effects: As Wegovy is specifically approved for weight management, it may cause more noticeable effects related to weight loss, such as dizziness due to rapid weight loss or changes in appetite.
- Hypoglycemia risk: Ozempic, being primarily used for diabetes management, may have a higher risk of hypoglycemia, especially when used in combination with other diabetes medications.
- Injection site reactions: These may be more common with Wegovy due to the higher volume of medication being injected.
- Cardiovascular effects: Wegovy has been studied and approved for reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight, which is not an approved indication for Ozempic.
It’s important to note that while the side effect profiles are similar due to the shared active ingredient, individual experiences may vary. The higher dosage used in Wegovy generally leads to more pronounced effects, both in terms of weight loss and potential side effects. As always, patients should consult with their healthcare providers about the potential risks and benefits of these medications based on their individual health status and treatment goals.
How do the costs of Wegovy and Ozempic compare?
Here’s a comparison of the costs of Wegovy and Ozempic:
List prices:
- Wegovy: The list price is approximately $1,349 per month or $16,188 per year .
- Ozempic: The list price is around $969 per month for a four-week supply .
Without insurance:
- Wegovy: Can cost around $1,350 for a 28-day supply .
- Ozempic: Costs approximately $935.77 for a one-month supply .
With insurance:
- Wegovy: Eligible commercially insured patients may pay as little as $0 per 28-day supply with a maximum savings of $225 per fill for 12 fills .
- Ozempic: Can cost as little as $25 for a monthly supply with insurance coverage .
Savings programs:
- Both medications offer savings programs. For example, Novo Nordisk provides a savings card for Ozempic that can allow savings up to $150 per 1-month prescription, $300 per 2-month prescription, or $450 per 3-month prescription .
Patient assistance programs:
- Both Wegovy and Ozempic have patient assistance programs that can provide the medication at no cost for eligible individuals who meet specific criteria, such as being uninsured and meeting certain income requirements .
Actual prices paid:
- It’s important to note that the actual prices paid for these medications are often lower than the list prices due to negotiations between pharmaceutical companies and insurers or pharmacy benefit managers .
International price differences:
- These medications are often significantly cheaper in other countries. For example, they are available at much lower prices in Mexico .
Future price trends:
- With increasing competition in the market for weight loss and diabetes drugs, there’s potential for prices to decrease in the future .
While both Wegovy and Ozempic are expensive medications, Wegovy generally has a higher list price. However, the actual cost to patients can vary greatly depending on insurance coverage, use of savings programs, and eligibility for patient assistance programs. Both drugs offer various options to help reduce out-of-pocket costs for patients.
The bottom line
In conclusion, Wegovy represents a significant advancement in the medical treatment of obesity and overweight. By targeting the brain’s appetite regulation centers, it offers a powerful tool for weight loss and cardiovascular risk reduction when combined with lifestyle modifications.
However, as with any medication, it should be used under the guidance of a healthcare professional and in conjunction with a healthy diet and exercise regimen for optimal results.